Continuous versus intermittent β-lactam infusion in severe sepsis. A meta-analysis of individual patient data from randomized trials.
The DOI matches its Crossref record; 46 of the 46 references it cites were found in a registry or an index.
Abstract
Rationale Optimization of β-lactam antibiotic dosing for critically ill patients is an intervention that may improve outcomes in severe sepsis. Objectives In this individual patient data meta-analysis of critically ill patients with severe sepsis, we aimed to compare clinical outcomes of those treated with continuous versus intermittent infusion of β-lactam antibiotics. Methods We identified relevant randomized controlled trials comparing continuous versus intermittent infusion of β-lactam antibiotics in critically ill patients with severe sepsis. We assessed the quality of the studies according to four criteria. We combined individual patient data from studies and assessed data integrity for common baseline demographics and study endpoints, including hospital mortality censored at 30 days and clinical cure. We then determined the pooled estimates of effect and investigated factors associated with hospital mortality in multivariable analysis. Measurements and main results We identified three randomized controlled trials in which researchers recruited a total of 632 patients with severe sepsis. The two groups were well balanced in terms of age, sex, and illness severity. The rates of hospital mortality and clinical cure for the continuous versus intermittent infusion groups were 19.6% versus 26.3% (relative risk, 0.74; 95% confidence interval, 0.56-1.00; P = 0.045) and 55.4% versus 46.3% (relative risk, 1.20; 95% confidence interval, 1.03-1.40; P = 0.021), respectively. In a m…
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The desirable effects of empiric antiviral therapy are unknown, and as for other antimicrobial agents there is a risk of undesirable effects (165).”
From Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock 2021. (2021) · cites this paper as [165]
In the citing paper
“Two meta-analyses reported similar results supporting reduced short-term mortality (RR 0.70; 95% CI 0.57–0.87) with prolonged infusion of beta-lactams [232, 233].”
From Surviving sepsis campaign: international guidelines for management of sepsis and septic shock 2021 (2021) · cites this paper as [232]
Citations
Cites
Preferred Reporting Items for Systematic Reviews and Meta-Analyses: the PRISMA statement
Moher, D., Liberati, A., Tetzlaff, J., Altman, D. G., & for the PRISMA Group (2009) · BMJ · doi:10.1136/bmj.b2535 · Cited by 83,823
Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement
Moher, D., Liberati, A., Tetzlaff, J., Altman, D. G., & The PRISMA Group (2009) · PLoS Medicine · doi:10.1371/journal.pmed.1000097 · Cited by 64,042
Preferred reporting items for systematic reviews and meta-analyses: the PRISMA Statement.
(2009) · PubMed Central · Cited by 44,859
Cochrane Handbook for Systematic Reviews of Interventions: Cochrane Book Series
(2008) · doi:10.1002/9780470712184 · Cited by 25,048
Classification and Regression Trees.
Gordon, A. D., Breiman, L., Friedman, J. H., Olshen, R. A., & Stone, C. J. (1984) · Biometrics · doi:10.2307/2530946 · Cited by 23,522
Magiorakos, A.-P., Srinivasan, A., Carey, R. B., Carmeli, Y., Falagas, M. E., Giske, C. G., Harbarth, S., Hindler, J. F., Kahlmeter, G., Olsson-Liljequist, B., et al. (2012) · Clinical Microbiology and Infection · doi:10.1111/j.1469-0691.2011.03570.x · Cited by 14,449
APACHE II: A severity of disease classification system
KNAUS, W. A., DRAPER, E. A., WAGNER, D. P., & ZIMMERMAN, J. E. (1985) · Critical Care Medicine · doi:10.1097/00003246-198510000-00009 · Cited by 13,664
APACHE II-A Severity of Disease Classification System: Reply
Knaus, W. A., Draper, E. A., Wagner, D. P., & Zimmerman, J. E. (1986) · Critical Care Medicine · doi:10.1097/00003246-198608000-00028 · Cited by 13,376
Kumar, A., Roberts, D., Wood, K. E., Light, B., Parrillo, J. E., Sharma, S., Suppes, R., Feinstein, D., Zanotti, S., Taiberg, L., et al. (2006) · Critical Care Medicine · doi:10.1097/01.ccm.0000217961.75225.e9 · Cited by 6,109
Cochrane Handbook for Systematic Reviews of Interventions
Tarsilla, M. (2010) · Journal of MultiDisciplinary Evaluation · doi:10.56645/jmde.v6i14.284 · Cited by 5,178
Cited by
Items 201–300 of 380
Cojutti, P. G., Giuliano, S., Pascale, R., Angelini, J., Tascini, C., Viale, P., & Pea, F. (2023) · Microorganisms · doi:10.3390/microorganisms11122964 · Cited by 10
“However, this PK/PD target may be insufficient when treating severe MRSA infections, and more aggressive PK/PD targets up to 100% t > 4–8 × MIC are recommended nowadays for maximizing treatment with 24-continuous infusion (CI) beta-lactams among critically ill patients [13–15].”
BackgroundWicha, S. G., Kinast, C., Münchow, M., Wittova, S., Greppmair, S., Kunzelmann, A. K., Zöller, M., Paal, M., Vogeser, M., Habler, K., et al. (2024) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00451-24 · Cited by 10
“Our population had an overall preserved renal function with a median CLCRCG of 111 mL/min, and consequently, the estimated plasma CL of meropenem (11.1 L/h) was slightly higher than in intensive care populations with more impaired renal function [7.42 (25), 9.25 L/h (22)].”
Influentialβ-lactam dosing strategies: Think before you push
Liu, J., Rhodes, N. J., Roberts, J. A., Pais, G. M., Turner, B., Kiel, P. J., & Scheetz, M. H. (2020) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2020.106151 · Cited by 10
Self-citationEmerging concepts in the care of patients with cirrhosis and septic shock
Jiménez, J. V., García–Tsao, G., & Saffo, S. (2023) · World Journal of Hepatology · doi:10.4254/wjh.v15.i4.497 · Cited by 13
Prolonged Beta-Lactam Infusions in Children: A Systematic Review and Meta-Analysis
Briand, A., Bernier, L., Pincivy, A., Roumeliotis, N., Autmizguine, J., Marsot, A., Métras, M., & Thibault, C. (2024) · The Journal of Pediatrics · doi:10.1016/j.jpeds.2024.114220 · Cited by 10
Rademacher, J., Ewig, S., Grabein, B., Nachtigall, I., Abele‐Horn, M., Deja, M., Gaßner, M., Gatermann, S. G., Geffers, C., Gerlach, H., et al. (2025) · Pneumologie · doi:10.1055/a-2541-9872 · Cited by 23
Willam, C., Abu-Tair, M., Bayer, M., Bellmann, R., Brunkhorst, F. M., Custodis, F., Galle, J. C., Hermes, C., Joannidis, M., John, S., et al. (2025) · Medizinische Klinik - Intensivmedizin und Notfallmedizin · doi:10.1007/s00063-025-01293-6 · Cited by 9
Maternal Sepsis Review and Update
Yahya, F. B., Abel, A. L. V., Brakke, B. D., Palraj, R., Szymanski, L. M., Chapman, M. L., Tobah, Y. B., Rajapakse, N., & Dinnes, L. (2025) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2025.03.024 · Cited by 14
Charlier, C., Souhail, B., Dauger, S., Woerther, P., Bleibtreu, A., Caséris, M., Chosidow, O., Bertolus, C., Hua, C., Monsel, G., et al. (2025) · Critical Care · doi:10.1186/s13054-025-05664-5 · Cited by 11
“It is recommended that an initial full daily dose be administered based on patient weight (regardless of creatinine clearance), followed by daily therapeutic drug monitoring for adjustments (Table 1) [50–52].”
Setiawan, E., Cotta, M. O., Abdul-Aziz, M. H., Widjanarko, D., Sosilya, H., Lukas, D. L., Wallis, S. C., Parker, S. L., & Roberts, J. A. (2023) · Clinical Pharmacokinetics · doi:10.1007/s40262-023-01219-5 · Cited by 10
“However, whether 4-h infusions result in better clinical outcomes in non-ICU patients requires further investigation [36, 37].”
BackgroundSelf-citationGómez‐Junyent, J., Rigo-Bonnin, R. F., Benavent, E., Soldevila, L., Padullés, A., Cabo, X., Tubau, F., Ariza, J., & Murillo, Ó. (2020) · European Journal of Drug Metabolism and Pharmacokinetics · doi:10.1007/s13318-020-00625-5 · Cited by 9
Chiriac, U., Frey, O. R., Roehr, A. C., Koeberer, A., Gronau, P., Fuchs, T., Roberts, J. A., & Brinkmann, A. (2021) · Medicine · doi:10.1097/md.0000000000026253 · Cited by 10
Self-citationMeenks, S. D., Punt, N. C., le Noble, J. L. M. L., Foudraine, N. A., Neef, K., & Janssen, P. K. C. (2023) · Critical Care · doi:10.1186/s13054-023-04353-5 · Cited by 9
Berrino, P. M., Gatti, M., Rinaldi, M., Brunocilla, E., Viale, P., & Pea, F. (2023) · Antibiotics · doi:10.3390/antibiotics12091388 · Cited by 9
Ribera, A., Soldevila, L., Rigo-Bonnin, R. F., Tubau, F., Padullés, A., Gómez‐Junyent, J., Ariza, J., & Murillo, Ó. (2018) · Infection · doi:10.1007/s15010-018-1116-6 · Cited by 9
A Multinational Randomized Trial of Mega-Dose Esomeprazole as Anti-Inflammatory Agent in Sepsis
Monti, G., Carta, S., Kotani, Y., Bruni, A., Konkayeva, M. E., Guarracino, F., Yakovlev, A., Cucciolini, G., Shemetova, M. M., Scapol, S., et al. (2025) · Critical Care Medicine · doi:10.1097/ccm.0000000000006720 · Cited by 8
Self-citationdos Santos, C. C., Heunks, L. M. A., & Wunsch, H. (2017) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201701-0164up · Cited by 8
Early Empirical Use of Broad-Spectrum Antibiotics in Sepsis
Chang, J. L., Pearson, J. C., & Rhee, C. (2022) · Current Infectious Disease Reports · doi:10.1007/s11908-022-00777-2 · Cited by 13
Martínez-Casanova, J., Pitarch, E. E., Colom, H., Gumucio-Sanguino, V. D., Sacristán, S. C., Shaw, E., Maisterra-Santos, K., Sabater‐Riera, J., Pérez-Fernández, X. L., Rigo-Bonnin, R. F., et al. (2023) · Antibiotics · doi:10.3390/antibiotics12030531 · Cited by 9
“However, a meta-analysis from randomized trials in patients with severe sepsis demonstrated a lower mortality rate in patients treated with beta-lactam by CI with respect to those treated by II [39].”
ResultSOP Individuelle Dosierung und Applikation von Antiinfektiva auf der Intensivstation
Röhr, A. C., Koeberer, A., Fuchs, T., von Freyberg, P., Frey, O. R., & Brinkmann, A. (2018) · Intensivmedizin up2date · doi:10.1055/a-0626-8184 · Cited by 9
“Lancet Infect Dis 2018; 18: 108–120 [21] Roberts JA, Abdul-Aziz MH, Davis JS et al.”
BackgroundNiibe, Y., Suzuki, T., Yamazaki, S., Uchida, M., Suzuki, T., Takahashi, N., Hattori, N., Nakada, T., & Ishii, I. (2021) · Journal of Infection and Chemotherapy · doi:10.1016/j.jiac.2021.12.017 · Cited by 8
Tait, J. R., Bilal, H., Rogers, K. E., Lang, Y., Kim, T., Zhou, J., Wallis, S. C., Bulitta, J. B., Kirkpatrick, C. M. J., Paterson, D. L., et al. (2022) · Antibiotics · doi:10.3390/antibiotics11010101 · Cited by 8
Self-citationLiebchen, U., Weinelt, F. A., Scharf, C., Schroeder, I., Paal, M., Zoller, M., Kloft, C., Jung, J., & Michelet, R. (2021) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01831-21 · Cited by 9
“Our results strongly support the available evidence in the literature that a better PK/PD target attainment is achieved with CI (30).”
ResultPopulation Pharmacokinetic Study of Benzylpenicillin in Critically Unwell Adults
Shah, R. V., Kipper, K., Baker, E. H., Barker, C. I. S., Oldfield, I., Philips, B. J., Johnston, A. E., Lipman, J., Rhodes, A., Basarab, M., et al. (2023) · Antibiotics · doi:10.3390/antibiotics12040643 · Cited by 7
“Beta-lactam antibiotics such as benzylpenicillin display time-dependent activity—bacterial killing and treatment efficacy positively correlate with the proportion of time that free drug concentration is above the minimum inhibitory concentration (%fT>MIC) of the organism being treated [4,7,8].”
BackgroundSelf-citationLagarde, C., Bouras, M., Floch, R. L., Hourmant, Y., Grillot, N., Bourdiol, A., Mahe, P. J., Latte, D. D. D., Grégoire, M., Dailly, É., et al. (2023) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkad094 · Cited by 8
Wang, Y., Li, H., Wang, D., Li, Y., Shen, Y., Fu, Y., Li, Y., Gao, M. Q., & Zhang, D. (2024) · Scientific Reports · doi:10.1038/s41598-024-60909-7 · Cited by 11
Meta-analysis on safety of standard vs. prolonged infusion of beta-lactams
Rolain, H., Schwartz, Z., Jubrail, R., Downes, K. J., Hong, L. T., FakhriRavari, A., Rhodes, N. J., & Scheetz, M. H. (2024) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2024.107309 · Cited by 7
Gonçalves-Pereira, J., Fernandes, J., Mendes, T. F., Gonzalez, F. A., & Fernandes, S. M. (2024) · Antibiotics · doi:10.3390/antibiotics13090853 · Cited by 10
“Another strategy is to administer an initial intravenous loading dose, at the onset of treatment, followed by prolonged (continuous or extended) β -lactam infusion to maximize PK/PD target attainment [7,12,14].”
BackgroundMaarbjerg, S. F., Thorsted, A., Friberg, L. E., Nielsen, E. I., Wang, M., Schrøder, H. D., & Albertsen, B. K. (2021) · Cancer Reports · doi:10.1002/cnr2.1585 · Cited by 8
Fresán, D., Luque, S., Benítez-Cano, A., Sorlí, L., Montero, M., de Antonio-Cuscó, M., Vega, V., Roberts, J. A., Horcajada, J. P., & Grau, S. (2023) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkad296 · Cited by 7
Self-citationDale, E. L., & Hultman, C. S. (2017) · Clinics in Plastic Surgery · doi:10.1016/j.cps.2017.02.015 · Cited by 8
Bos, J. C., van Hest, R. M., Mistício, M. C., Nunguiane, G., Lang, C. N., Beirão, J. C., Mathôt, R. A. A., & Prins, J. M. (2017) · Clinical Infectious Diseases · doi:10.1093/cid/cix961 · Cited by 7
Kalkulierte parenterale Initialtherapie bakterieller Infektionen: Sepsis
Bodmann, K., Höhl, R., Krüger, W. A., Grabein, B., & Graninger, W. (2020) · GMS infectious diseases · doi:10.3205/id000053 · Cited by 7
Rafailidis, P. I., & Falagas, M. E. (2020) · Expert Review of Anti-infective Therapy · doi:10.1080/14787210.2020.1776113 · Cited by 8
Time Above All Else: Pharmacodynamic Analysis of β‐Lactams in Critically Ill Patients
Landmesser, K. B., Clark, J. A., & Burgess, D. S. (2021) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.1977 · Cited by 8
Hammond, D. A., McCreary, E. K., Rech, M. A., Smith, M. N., Yeo, Q. M., Lusardi, K. T., Rhodes, N. J., Swanson, J. M., & Bland, C. M. (2019) · JACCP JOURNAL OF THE AMERICAN COLLEGE OF CLINICAL PHARMACY · doi:10.1002/jac5.1084 · Cited by 7
Peng, Y., Liu, Y., Cheng, Z., Zhang, Q., Xie, F., Zhu, S., & Li, S. (2025) · Drug Design Development and Therapy · doi:10.2147/dddt.s489603 · Cited by 7
“13,14 The Surviving Sepsis Campaign advocates for prolonged beta-lactam infusion (following an initial bolus) over traditional bolus infusion for adults with sepsis or septic shock.”
Dzierba, A. L., Muir, J., Dilawri, A., & Buckley, M. S. (2023) · JACCP JOURNAL OF THE AMERICAN COLLEGE OF CLINICAL PHARMACY · doi:10.1002/jac5.1780 · Cited by 6
“In critically ill patients, optimal beta-lactam dosing strategies may include continuous or prolonged infusions, which have demonstrated improved clinical outcomes when compared with intermittent dosing.(34,35) Additionally, dosing strategies guided by TDM”
BackgroundRademacher, J., Ewig, S., Grabein, B., Nachtigall, I., Abele‐Horn, M., Deja, M., Gaßner, M., Gatermann, S. G., Geffers, C., Gerlach, H., et al. (2024) · Infection · doi:10.1007/s15010-024-02358-y · Cited by 7
“…reviews were identified that examined the efficacy and safety of prolonged administration (3–4 h or continuous infusion) with intermittent bolus administration of beta-lactam anti-biotics on mortality, clinical recovery, side effects and the occurrence of antibiotic-resistant bacteria [63–67].”
Management of Complex Infections in Hemophagocytic Lymphohistiocytosis in Adults
Zhang, Y., Cheng, Z., Hu, Y., & Tang, L. V. (2023) · Microorganisms · doi:10.3390/microorganisms11071694 · Cited by 8
“For beta-lactams, good anti-infective therapy and prognosis are associated with a longer duration of plasma concentrations above the pathogenic MIC, and studies have shown that the continuous infusion of beta-lactam antibiotics in patients with severe sepsis reduces in-hospital mortality compared with intermittent adm…”
BackgroundLaffont-Lozes, P., Naciri, T., Pantel, A., Martin, A., Pruvot-Occean, A.-S., Haignère, V., Loubet, P., Sotto, A., & Larcher, R. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1347306 · Cited by 6
Giacobbe, D. R., Roberts, J. A., Abdul-Aziz, M. H., de Montmollin, É., Timsit, J., & Bassetti, M. (2022) · Expert Review of Anti-infective Therapy · doi:10.1080/14787210.2022.2063838 · Cited by 6
Self-citationMartín‐Loeches, I., Metersky, M. L., Kalil, A. C., Pezzani, M. D., & Torres, A. (2020) · Expert Review of Anti-infective Therapy · doi:10.1080/14787210.2021.1857730 · Cited by 7
Resolving the Dilemma on Continuous vs Intermittent β-Lactam Antibiotics in Sepsis
Wiersinga, W. J., & van Agtmael, M. A. (2024) · JAMA · doi:10.1001/jama.2024.10168 · Cited by 6
Razazi, K., Berti, E., Cecchini, J., Carteaux, G., Habibi, A., Bartolucci, P., Arrestier, R., Gendreau, S., de Prost, N., Lesne-Hulin, A., et al. (2024) · PLoS ONE · doi:10.1371/journal.pone.0302298 · Cited by 5
Konkayev, A. K., Kadralinova, A., Azimova, B., Tazhibaeva, D., Yeltayeva, A. A., & Konkayeva, M. E. (2024) · Medicina · doi:10.3390/medicina60060929 · Cited by 5
“In a meta-analysis involving 632 patients with severe sepsis, the authors concluded that the continuous administration of beta-lactam antibiotics was associated with a reduction in hospital mortality [15].”
BackgroundLandry, D. L., Eltonsy, S., Jalbert, L. P., Girouard, G., Couture, J., & Bélanger, M. F. (2019) · Journal of the Association of Medical Microbiology and Infectious Disease Canada · doi:10.3138/jammi.2018-0039 · Cited by 5
Lin, C., Wu, J., Huang, P., Sung, H., Tung, Y., Lai, C.-C., Wei, Y., & Fu, P. (2024) · Expert Review of Anti-infective Therapy · doi:10.1080/14787210.2024.2324940 · Cited by 5
“However, this association did not remain significant after performing multivariate analyses when considering clinical cure as an independent outcome [7].”
InfluentialCarrimycin ameliorates lipopolysaccharide and cecal ligation and puncture-induced sepsis in mice
Lai, J., LIANG, J., Kunsen, C. H. E. N., Guan, B., Linqin, C. H. E. N., Linqin, C. H. E. N., Jiqiang, F. A. N., Zhang, Y., Qiumei, L. I., Su, J., et al. (2024) · Chinese Journal of Natural Medicines · doi:10.1016/s1875-5364(24)60600-x · Cited by 7
Ramos, J. R., & Ramírez, P. (2022) · Medicina Intensiva (English Edition) · doi:10.1016/j.medine.2022.09.004 · Cited by 8
Richter, D. C., Brenner, T., Brinkmann, A., Grabein, B., Hochreiter, M., Heininger, A., Störzinger, D., Briegel, J., Pletz, M. W., Weigand, M. A., et al. (2019) · Der Anaesthesist · doi:10.1007/s00101-019-00646-z · Cited by 7
Meropenem serum concentrations in intensive care patients: a retrospective analysis
Ďuricová, J., Kacířová, I., & Brozmanová, H. (2020) · Česká a slovenská farmacie · doi:10.36290/csf.2020.032 · Cited by 5
Mu, Z., Wang, J., & Mu, E. (2025) · Journal of Infection and Chemotherapy · doi:10.1016/j.jiac.2025.102634 · Cited by 4
Wang, Y., Li, Y., Gao, M. Q., Zhang, M., Li, Y., Wang, D., Li, X., Zhang, C., Fu, Y., Li, H., et al. (2025) · Frontiers in Medicine · doi:10.3389/fmed.2025.1580116 · Cited by 4
“Interestingly, this result contradicts the meta-analysis results reported by Roberts et al. (12), Zhao et al. (10) and other meta-analyses (11, 13).”
Less is more: critically ill status is not a carte blanche for unlimited antibiotic use
Kalil, A. C., & Timsit, J. (2020) · Intensive Care Medicine · doi:10.1007/s00134-020-06260-7 · Cited by 5
“The benefits from the PK/ PD approach have also been demonstrated in patients with sepsis and septic shock [9, 10].”
Model antibiotic use to improve outcomes
Fullerton, J. N., Pasqua, O. E. D., & Likić, R. (2020) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.14559 · Cited by 4
“dosing in the critical care setting for patients with sepsis: a recent meta-analysis demonstrating that infusions lead to a higher cure rate and lower hospital mortality.(2)”
BackgroundOptimizing Betalactam Clinical Response by Using a Continuous Infusion: A Comprehensive Review
Diamantis, S., Chakvetadze, C., de Pontfarcy, A., & Matta, M. (2023) · Antibiotics · doi:10.3390/antibiotics12061052 · Cited by 4
“optimizing the fT > MIC ratio, such as using a continuous infusion (CI) rather than an intermittent infusion (II) of betalactams, as CI is associated with a higher fT > MIC ratio [15], although it does not always translate into a better clinical outcome.”
BackgroundMethodAt the Intersection of Critical Care and Infectious Diseases: The Year in Review
Sabo, S. R., Venkatramanan, A., & Shorr, A. F. (2024) · Biomedicines · doi:10.3390/biomedicines12030562 · Cited by 5
“A meta-analysis of multiple trials exploring this question concluded that continuous or extended infusion likely benefits patients, but the magnitude of the impact was potentially small and moderated by a number of factors including severity of illness and the type of infecting pathogen [32].”
BackgroundRout, J., Brysiewicz, P., & Essack, S. Y. (2024) · Intensive and Critical Care Nursing · doi:10.1016/j.iccn.2024.103786 · Cited by 4
Johnson, E. G., Ortiz, K. M., Adams, D. T., Kaur, S. S., Faust, A. C., Yang, H. J., Álvarez, C. A., & Hall, R. G. (2024) · Antibiotics · doi:10.3390/antibiotics13090835 · Cited by 4
Ceftobiprole in Critically Ill Patients: Proposal for New Dosage Regimens
Baklouti, S., Mané, C., Bennis, Y., Luyt, C. E., Joseph, C., Ruiz, S., Guilhaumou, R., Concordet, D., Zahr, N., & Gandia, P. (2025) · Therapeutic Drug Monitoring · doi:10.1097/ftd.0000000000001338 · Cited by 4
„Antibiotic Stewardship“: Maßnahmen zur Optimierung der Verordnung von Antiinfektiva
Lanckohr, C., & Bracht, H. (2018) · Der Anaesthesist · doi:10.1007/s00101-017-0398-x · Cited by 5
Closed-loop control of continuous piperacillin delivery: An in silico study
Herrero, P., Wilson, R. C., Armiger, R., Roberts, J. A., Holmes, A. H., Georgiou, P., & Rawson, T. M. (2022) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2022.1015389 · Cited by 4
“The data analysed in this study was obtained from Roberts et al. (2016). Datasets are available on request: The raw data supporting the conclusions of this article will be made available by the authors, without undue reservation.”
Self-citationShould Prolonged Infusion of ß-Lactams Become Standard of Practice?
Haj, R., Leung, E., & Zvonar, R. K. (2017) · The Canadian Journal of Hospital Pharmacy · doi:10.4212/cjhp.v70i2.1650 · Cited by 5
Nosokomiale Pneumonie – neue Leitlinien
Kramme, E., & Dalhoff, K. (2019) · DMW - Deutsche Medizinische Wochenschrift · doi:10.1055/a-0652-8351 · Cited by 4
Fawaz, S., Barton, S., Whitney, L., & Nabhani‐Gebara, S. (2020) · JAC-Antimicrobial Resistance · doi:10.1093/jacamr/dlaa083 · Cited by 4
Therapeutisches Drug Monitoring (TDM) in der antiinfektiven Therapie – von der Theorie zur Praxis
Brinkmann, A., Röhr, A. C., Richter, D., Chiriac, U., & Frey, O. R. (2021) · Krankenhaushygiene up2date · doi:10.1055/a-1173-5813 · Cited by 6
Winiszewski, H., Despres, C., Puyraveau, M., Lagoutte‐Renosi, J., Montange, D., Besch, G., Pili‐Floury, S., Chaignat, C., Labro, G., Vettoretti, L., et al. (2021) · Journal of Critical Care · doi:10.1016/j.jcrc.2021.10.023 · Cited by 4
Sumi, C. D., Heffernan, A. J., Naicker, S., Cottrell, K., Wallis, S. C., Lipman, J., Harris, P. N. A., Sime, F. B., & Roberts, J. A. (2022) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkac273 · Cited by 4
Self-citationBartoletti, M., Lewis, R. E., Giannella, M., Tedeschi, S., & Viale, P. (2018) · Expert Review of Anti-infective Therapy · doi:10.1080/14787210.2018.1523716 · Cited by 5
Crass, R. L., Williams, P. G., & Roberts, J. A. (2019) · Anaesthesia Critical Care & Pain Medicine · doi:10.1016/j.accpm.2019.12.008 · Cited by 5
Self-citationStewart, S. D., Allen, S. J., Eisenberg, B., Sakakeeny, K., Hammond, T. N., Schneider, B., Mochel, J. P., & Zhou, T. (2022) · American Journal of Veterinary Research · doi:10.2460/ajvr.22.08.0139 · Cited by 3
“34 A future application of this data could be for the development of therapeutic drug monitoring protocols.”
BackgroundBüyükyanbolu, E., Gill, C. M., Genç, L., Karakuş, M., Cömert, F., Otlu, B., Aktaş, E., & Nicolau, D. P. (2024) · European Journal of Clinical Microbiology & Infectious Diseases · doi:10.1007/s10096-024-04990-w · Cited by 3
“A meta-analysis demonstrated a statistically significant dif - ference in clinical improvement and mortality favoring continuous beta-lactam infusion over intermittent infusion in severe sepsis [23].”
“Dusting Off the Cobwebs”: Rethinking How We Use New Antibiotics
Keck, J. M., Schultz, J., & Viteri, A. (2025) · Antibiotics · doi:10.3390/antibiotics14090862 · Cited by 4
“This includes extended or continuous infusions, which can enhance target attainment in critically ill patients with altered drug distribution and clearance [182–186].”
Diagnosis and Management of Sepsis and Septic Shock: An Evidence-Based Review
Tulli, G. (2019) · Springer eBooks · doi:10.1007/978-3-319-94189-9_9 · Cited by 4
Major Publications in the Critical Care Pharmacotherapy Literature: 2021
Wieruszewski, P. M., Brickett, L. M., Dayal, L., Egan, A. M., Khanna, A. K., Lemieux, S. M., Mukkera, S. R., Patel, J. S., Reichert, M., Reynolds, T. R., et al. (2022) · Critical Care Explorations · doi:10.1097/cce.0000000000000823 · Cited by 4
Therapeutisches Drug-Monitoring in der antiinfektiven Therapie
Brinkmann, A., Röhr, A. C., Krüger, W. A., & Frey, O. R. (2017) · Krankenhaushygiene up2date · doi:10.1055/s-0042-123738 · Cited by 5
“[31] Roberts JA, Abdul-Aziz MH, Davis JS et al.”
BackgroundCurrent Clinical Controversies in the Management of Sepsis
Cohen, J. (2016) · The Journal of the Royal College of Physicians of Edinburgh · doi:10.4997/jrcpe.2016.413 · Cited by 3
Therapeutic Drug Monitoring: More Than Avoiding Toxicity
Stojanova, J., & Luque, S. (2017) · Springer eBooks · doi:10.1007/978-981-10-5336-8_9 · Cited by 3
β-lactam prolonged infusion: it's time to implement!
Paul, M., & Theuretzbacher, U. (2017) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(17)30614-x · Cited by 4
In silico evaluation of a beta‐lactam dosing guideline among adults with serious infections
Williams, P. G., Cotta, M. O., Abdul-Aziz, M. H., Wilks, K. M., Farkas, A., & Roberts, J. A. (2023) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.2753 · Cited by 4
Self-citationThe Answer for Inhaled Antibiotics in Pneumonia Is Still Blowing in the Wind
Shorr, A. F., & Zilberberg, M. D. (2017) · CHEST Journal · doi:10.1016/j.chest.2016.11.034 · Cited by 3
“Certainly studies indicate that applying principles of pharmacokinetics and pharmacodynamics to patients in the ICU can enhance results.(7,8) However, the overall value and impact of this stratagem has yet to be clearly defined.”
Transplant Infectious Diseases
Chan, G. C., Lynch, B., Murray, M., & Hannan, M. M. (2023) · Wiley eBooks · doi:10.1002/9781119633884.ch92 · Cited by 3
Metsä‐Simola, N., Saarenketo, J., Lehtonen, H., Broman, N., Häggblom, T., Björklöf, P., Sariola, S., & Valta, M. P. (2024) · European Journal of Public Health · doi:10.1093/eurpub/ckae112 · Cited by 2
Adamiszak, A., Bartkowska‐Śniatkowska, A., Grześkowiak, E., & Bienert, A. (2024) · Anaesthesiology Intensive Therapy · doi:10.5114/ait.2024.141332 · Cited by 2
Li, Y., Roberts, J. A., Abdul-Aziz, M. H., & Sime, F. B. (2025) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00732-25 · Cited by 4
“Reviews of critically ill sepsis patients by Chen et al. (47) and Roberts et al. (48) suggested significant advantages of mortality and clinical cure rates.”
Self-citationYeoh, D. K., Boast, A., Wen, S. C.-H., Williams, P. C. M., VOSS, L. M., Ritchie, B. K., Mostaghim, M., Lutui, F., Lei, A., Lai, T., et al. (2025) · The Lancet Regional Health - Western Pacific · doi:10.1016/j.lanwpc.2025.101735 · Cited by 3
Inamdar, A., Beeraka, N. M., Vikram, P. R. H., Gurupadayya, B. M., Sanathan, S. R., Prashant, A., Kumar, T. P., Nikolenko, V. N., Reddy, Y. P., Kandula, D. R., et al. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2026.1761582 · Cited by 3
“…(Roberts et al., 2014a; Skhirtladze et al., 2006), saliva (Shipkova and Jamoussi, 2022), tears (Nordmann et al., 2011), and interstitial fluid (ISF) (Nordmann et al., 2011; Roberts et al., 2016), which are rich in clinically relevant biomarkers and accessible without the need for venipuncture.”
Klyasova, G. A. (2020) · Oncohematology · doi:10.17650/1818-8346-2020-15-2-92-107 · Cited by 2
“Пролонгированная инфузия βлактама в сравнении с коротким введением препарата в лечении сепсиса или тяжелых инфекций, вызванных грамотрицатель ными полирезистентными бактериями, приводила к увеличению частоты излечений (55,4 % против 46,3 %; p = 0,021) и снижению летальных исходов (19,6 % про тив 26,3 %; р = 0,045)…”
Salehi, M., Rezazade-Moayed, F., Khalili, H., Hemati, H., Aghdami, N., Dashtkoohi, M., Dashtkoohi, M., Beigmohammadi, M. T., Ramezani, M., Hajiabdolbaghi, M., et al. (2023) · Future Microbiology · doi:10.2217/fmb-2022-0170 · Cited by 3
ALRJOOB, M., ALKHATIB, A., Padappayil, R. P., Bader, H., Du, D. T., & Patton, C. D. (2023) · Clinical Immunology Communications · doi:10.1016/j.clicom.2023.07.005 · Cited by 2
Tamma, P. D., Miller, M. A., & Cosgrove, S. E. (2021) · Annals of the American Thoracic Society · doi:10.1513/annalsats.202005-484ip · Cited by 3
Matusik, É., Lambiotte, F., Toné, A., & Lemtir, J. (2020) · Annales Pharmaceutiques Françaises · doi:10.1016/j.pharma.2020.11.011 · Cited by 5
Ramos, J. R., & Galleymore, P. R. (2022) · Medicina Intensiva · doi:10.1016/j.medin.2022.07.007 · Cited by 5
Wenker, S. A. M., Alabdulkarim, N., Readman, J., Slob, E. M. A., Satta, G., Ali, S., Gadher, N., Shulman, R. I., & Standing, J. F. (2024) · JAC-Antimicrobial Resistance · doi:10.1093/jacamr/dlae036 · Cited by 2
“17 18 A limitation of this study was that it lacked adjustment for ta-zobactam ’ s influence on piperacillin susceptibility.”
BackgroundJirasomprasert, T., Tian, L., You, D., Wang, Y., Dong, L., Zhang, Y.-H., Hao, G., van den Anker, J., Wu, Y., Tang, B., et al. (2024) · Pediatric Drugs · doi:10.1007/s40272-024-00664-4 · Cited by 2
“If the current dosing regimen was underdosed, the dosage was altered by an increased dose, frequency, or infusion time to get the optimal dosing regimen [30–32].”
Intensivmedizinische Studien aus 2016/2017
Reuß, C. J., Bernhard, M., Beynon, C., Hecker, A., Jungk, C., Michalski, D., Nußhag, C., Weigand, M. A., & Brenner, T. (2017) · Der Anaesthesist · doi:10.1007/s00101-017-0339-8 · Cited by 2
“[34] durchgeführten Metaanalyse wurden die Ergebnisse dieser 3 Studien nun zusammengefasst und zeigten schließlich in der Gesamtauswertung eine signifikante Verschiebung des Behandlungsergebnisses hin zu einem Überlebensvorteil bei kontinuierlicher Gabe (. Abb.”
BackgroundTai, T., Yamamoto, T., Yamaguchi, K., Watanabe, M., Tanaka, H., Muraki, Y., & Kosaka, S. (2023) · Journal of Infection and Chemotherapy · doi:10.1016/j.jiac.2023.04.004 · Cited by 2
Evidenzbasierte, interdisziplinäre Behandlung der abdominellen Sepsis
Schmoch, T., Al‐Saeedi, M., Hecker, A., Richter, D., Brenner, T., Hackert, T., & Weigand, M. A. (2019) · Der Chirurg · doi:10.1007/s00104-019-0795-6 · Cited by 2
β-lactam microneedle array biosensors: a new technology on the horizon
Richter, D., & Weigand, M. A. (2019) · The Lancet Digital Health · doi:10.1016/s2589-7500(19)30126-8 · Cited by 3
Metadata
- Authors
- Roberts, J. A., Abdul-Aziz, M.-H., Davis, J. S., Dulhunty, J. M., Cotta, M. O., Myburgh, J., Bellomo, R., & Lipman, J.
- Affiliations
- The University of Queensland (AU)
- International Islamic University Malaysia (MY)
- John Hunter Hospital (AU)
- Redcliffe Hospital (AU)
- The George Institute for Global Health (GB)
- Austin Hospital (AU)
- Department of Intensive Care Medicine and
- Corresponding author
- Roberts, Jason A.
- ORCID
- Venue
- American Journal of Respiratory and Critical Care Medicine
- Publisher
- Oxford University Press (OUP)
- Published
- 2016-09
- Volume
- 194
- Issue
- 6
- Pages
- 681-691
- ISSN
- 1073-449X (ISSN-L)
- 1535-4970
- OpenAlex
- W2298261704
- Cited by
- 379
- References
- 46
- Citations by year
- 2026: 11 · 2025: 18 · 2024: 45 · 2023: 51 · 2022: 37 · 2021: 44 · 2020: 43 · 2019: 38 · 2018: 38 · 2017: 39 · 2016: 15
- FWCI
- 4.99
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- American Journal of Respiratory and Critical Care Medicine (publishedVersion)
- PubMed (publishedVersion)
- NOVA (University of Newcastle Australia) (submittedVersion)
- Funders
- National Health and Medical Research Council of Australia (APP1048652)
- Australian National Health and Medical Research Council (APP1099452)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Antibiotics Pharmacokinetics and Efficacy
- Health Sciences › Medicine › Critical Care and Intensive Care Medicine › Sepsis Diagnosis and Treatment
- Health Sciences › Medicine › Oncology › Neutropenia and Cancer Infections
- Keywords
- severe sepsis, beta-lactam antibiotics, continuous infusion, intermittent infusion, antibiotic dosing, in-hospital mortality, clinical cure, critically ill patients, APACHE II score, renal replacement therapy, non-fermenting Gram-negative bacilli
- MeSH terms
- Aged, Anti-Bacterial Agents, Drug Administration Schedule, Female, Humans, Infusions, Intravenous, Male, Middle Aged, Proportional Hazards Models, Randomized Controlled Trials as Topic, Sepsis, beta-Lactams
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.